Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

First-Ever Dissolving Heart Stent Gets FDA Review

March 14, 2016 By Matthew Perrone, AP Health Writer

A disappearing medical implant will get a closer look from the Food and Drug Administration this week.

The FDA meets on Tuesday to review Abbott Laboratories’ first-of-a-kind heart stent that dissolves into the body after helping to clear fat-clogged arteries.

Abbott has asked the agency to approve its Absorb stent as an alternative to permanent, metal implants that have long been used to treat narrowing arteries that can lead to heart attack and death.

This undated image provided by Abbott shows their experimental heart stent “Absorb.” The FDA holds a meeting Tuesday, March 15, 2016, to review Abbott Laboratories’ first-of-a-kind heart stent that dissolves into the body after helping to clear fat-clogged arteries. (Credit: Weinberg-Clark Photography/Abbott via AP)

But regulators have questions about the safety and effectiveness of the experimental device. In a review posted late last week, FDA scientists noted that rates of cardiovascular complications were actually slightly higher with Absorb than with older stents tested in a company study. Additionally, complications were more likely to occur when Absorb was implanted into smaller arteries.

The agency will ask a panel of outside advisers to discuss the data and whether the device should be approved.

A positive opinion from the panel, while not binding, would bring Absorb one step closer to the U.S. market, where some 850,000 patients receive heart stents each year.

Stents are tiny, mesh-wire tubes that prop open arteries after they have been cleared of fatty plaque. They have grown into one of the most widely-used medical implants ever, but sales have been tempered by rare, risky complications.

Researchers first added drug-coatings to the devices in 2003 to prevent arteries from becoming reclogged after implantation. But subsequent studies showed that stented arteries could still develop blood clots, potentially triggering heart attack and death. To address that risk, Abbott and other device makers began developing dissolving stents that would slowly melt back into the body like stitches.

The Absorb stent, already sold in Europe, is made of a degradable material that’s designed to stay intact and release medicine for a year, then break down over the next two years.

In the company study submitted to FDA, patients who got Absorb fared as well as those receiving Abbott’s older metal stent, Xience. However, FDA reviewers noted that the rate of complications was actually slightly higher with Absorb — 7.8 percent of patients, versus 6.1 percent of patients with Xience. While that difference was not statistically significant, the FDA will ask advisers if it has implications for Absorb’s safety.

Additionally, FDA reviewers noted that complications appeared to increase when Absorb was placed in smaller blood vessels. That’s led Abbott to propose a warning to cardiologists not to use the device in vessels under a certain size, cautioning an increased risk of heart attack and clotting.

The FDA will ask its experts whether that warning is adequate.

Abbott followed patients for a year and measured a cluster of negative outcomes, including heart attack, repeat procedures to clear the artery and heart-related deaths. All patients in the study also received anti-clotting medications to prevent blood clots, standard medical practice for those receiving stents.

Despite negative questions from the FDA, Wells Fargo analyst Lawrence Biegelsen says federal approval is likely. But he doesn’t expect Absorb to be a major seller, “given its shortcomings — difficult to use, numerically worse outcomes versus Xience, higher rates of stent thrombosis.” He estimates the device will capture just 5 percent of the U.S. market for stents, according to a research note.

North Chicago-based Abbott competes against industry rivals Boston Scientific Corp., Medtronic Inc. and St. Jude Medical Inc. Abbott Laboratories shares slipped 29 cents to $40.08 in morning trading Monday.

Related Articles Read More >

A portrait of ResMed President and COO Rob Douglas
ResMed finds a solution to semiconductor shortage, as well as some humor in it
Johnson & Johnson Office of Digital Innovation Leader Peter Schulam
Imagining the future of cloud-connected medical devices with Johnson & Johnson leaders
Withings Body Scan
Withings plans launch for Body Scan smart scale platform
BinaxNow COVID-19 Ag Card
Time recognizes Abbott offerings among this year’s 100 best inventions

DeviceTalks Weekly.

June 24, 2022
How innovative design, commercial strategy is building Cala Trio’s bioelectronic medicine market
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech